{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268072","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.311832+00:00","generated_at":"2026-05-17T00:03:09.701994+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M","bullets":["Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).","End-of-Phase 2 FDA meeting by end 2025; two Phase 3 FOS trials to start Q3 2026.","Q3 net loss $26.9M (vs $17.5M YoY); R&D $22.3M, G&A $7.7M.","Cash, equivalents, and ST investments $513.0M; includes $269.4M net from September public offering.","Bipolar mania Phase 2 enrolling; topline expected H1 2027. DPNP trial on FDA clinical hold; update Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268072","json":"https://secwatch.observer/filing/0001193125-25-268072.json","markdown":"https://secwatch.observer/filing/0001193125-25-268072.md","text":"https://secwatch.observer/filing/0001193125-25-268072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/0001193125-25-268072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/rapp-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:03:09.701994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}